Erratum: Genetic association of lipids and lipid drug targets with abdominal aortic aneurysm: A meta-analysis (JAMA Cardiology DOI: 10.1001/jamacardio.2017.4293);Genetic association of lipids and lipid drug targets with abdominal aortic aneurysm ameta-Analysis

JAMA Cardiology

Volumn 3, Issue 1, 2018, Pages 26-33

  Harrison, Seamus C ^a,b   Holmes, Michael V ^b   Burgess, Stephen ^c   Asselbergs, Folkert W ^c   Jones, Gregory T ^d   Baas, Annette F ^e   Van't Hof, F N ^e   De Bakker, Paul I W ^f   Blankensteijn, Jan D ^g   Powell, Janet T ^e   Saratzis, Athanasios ^h   De Borst, Gert J ⁱ   Swerdlow, Daniel I ^j   Van Der Graaf, Yolanda ^e   Van Rij, Andre M ^f   Carey, David J ^k   Elmore, James R ^a   Tromp, Gerard ^l   Kuivaniemi, Helena ^a,m   Sayers, Robert D ⁿ   Samani, Nilesh J ^a   Bown, Matthew J ⁿ   Humphries, Steve E ^f   more..

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF OTAGO   (New Zealand)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ CHARING CROSS HOSPITAL   (United Kingdom)

^j UNIVERSITY OF LEICESTER   (United Kingdom)

^k HAMMERSMITH HOSPITAL   (United Kingdom)

^l WEIS CENTER FOR RESEARCH   (United States)

^m GEISINGER HEALTH SYSTEM   (United States)

ⁿ STELLENBOSCH UNIVERSITY   (South Africa)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE 9; TRIACYLGLYCEROL; ANTILIPEMIC AGENT;

ABDOMINAL AORTIC ANEURYSM; ARTICLE; CARDIOVASCULAR RISK; CETP GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HMGCR GENE; HUMAN; PATHOGENESIS; PCSK9 GENE; PLEIOTROPY; PREVALENCE; PRIORITY JOURNAL; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; GENETICS; GENOME-WIDE ASSOCIATION STUDY; LIPID METABOLISM; MENDELIAN RANDOMIZATION ANALYSIS; META ANALYSIS; METABOLISM; RISK FACTOR;

AORTIC ANEURYSM, ABDOMINAL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; GENOME-WIDE ASSOCIATION STUDY; HUMANS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; MENDELIAN RANDOMIZATION ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TRIGLYCERIDES;

EID: 85041475144     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2017.5132     Document Type: Erratum

References (49)

1. McPhee JT, Hill JS, Eslami MH. The impact of gender on presentation, therapy, and mortality of abdominal aortic aneurysm in the United States, 2001-2004. J Vasc Surg. 2007;45(5):891-899.
2. Ashton HA, Buxton MJ, Day NE, et al; Multicentre Aneurysm Screening Study Group. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: A randomised controlled trial. Lancet. 2002;360(9345):1531-1539.
3. LeFevre ML; U.S. Preventive Services Task Force. Screening for abdominal aortic aneurysm: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161(4):281-290.
4. National Health Service. Abdominal aortic aneurysm screening. http://www.nhs.uk/conditions /abdominal-Aortic-Aneurysm-screening/Pages /Introduction.aspx. Published July 24, 2017. Accessed October 24, 2017.
5. Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 125 million people. Lancet. 2014;383(9932):1899-1911.
6. Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: A cohort study in 19 million people. Lancet Diabetes Endocrinol. 2015;3(2):105-113.
7. Pujades-Rodriguez M, George J, Shah AD, et al. Heterogeneous associations between smoking and a wide range of initial presentations of cardiovascular disease in 1 937 360 people in England: lifetime risks and implications for risk prediction. Int J Epidemiol. 2015;44(1):129-141.
8. Helgadottir A, Thorleifsson G, Magnusson KP, et al. The same sequence variant on 9p21 associates withmyocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet. 2008;40(2):217-224.
9. Gretarsdottir S, Baas AF, Thorleifsson G, et al. Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. Nat Genet. 2010;42(8):692-697.
10. Bradley DT, Hughes AE, Badger SA, et al. A variant in LDLR is associated with abdominal aortic aneurysm. Circ Cardiovasc Genet. 2013;6(5): 498-504.
11. Jones GT, Bown MJ, Gretarsdottir S, et al. A sequence variant associated with sortilin-1 (SORT1) on 1p13.3 is independently associated with abdominal aortic aneurysm. Hum Mol Genet. 2013;22(14):2941-2947.
12. Harrison SC, Smith AJ, Jones GT, et al; Aneurysm Consortium. Interleukin-6 receptor pathways in abdominal aortic aneurysm. Eur Heart J. 2013;34(48):3707-3716.
13. BownMJ, Jones GT, Harrison SC, et al; CARDIoGRAM Consortium; Global BPgen Consortium; DIAGRAM Consortium; VRCNZ Consortium. Abdominal aortic aneurysm is associated with a variant in low-density lipoprotein receptor-related protein 1. Am J Hum Genet. 2011; 89(5):619-627.
14. Jones GT, Tromp G, Kuivaniemi H, et al. Meta-Analysis of genome-wide association studies for abdominal aortic aneurysm identifies four new disease-specific risk loci. Circ Res. 2017;120(2):341-353.
15. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363(9411):757-767.
16. Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45 (11):1345-1352.
17. Sarwar N, Sandhu MS, Ricketts SL, et al; Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies [published correction appears in Lancet. 2010;376(9735):90].
18. Lancet. 2010;375(9726): 1634-1639.
19. White J, Swerdlow DI, Preiss D, et al. Association of lipid fractions with risks for coronary artery disease and diabetes. JAMA Cardiol. 2016;1 (6):692-699.
20. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk ofmyocardial infarction: Amendelian randomisation study. Lancet. 2012;380(9841):572-580.
21. Barter PJ, Caulfield M, Eriksson M, et al; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109-2122.
22. Schwartz GG, Olsson AG, Abt M, et al; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089-2099.
23. Takagi H, Goto SN, Matsui M, Manabe H, Umemoto T. A further meta-Analysis of population-based screening for abdominal aortic aneurysm. J Vasc Surg. 2010;52(4):1103-1108.
24. Takagi H, Manabe H, Umemoto T. Ameta-Analysis of association between serum lipoproteins and abdominal aortic aneurysm. Am J Cardiol. 2010;106(5):753-754.
25. Freiberg MS, Arnold AM, Newman AB, Edwards MS, Kraemer KL, Kuller LH. Abdominal aortic aneurysms, increasing infrarenal aortic diameter, and risk of total mortality and incident cardiovascular disease events: 10-year follow-up data from the Cardiovascular Health Study. Circulation. 2008;117(8):1010-1017.
26. Bahia SS, Vidal-Diez A, Seshasai SR, et al. Cardiovascular risk prevention and all-cause mortality in primary care patients with an abdominal aortic aneurysm. Br J Surg. 2016;103(12): 1626-1633.
27. Gamboa CM, Safford MM, Levitan EB, et al. Statin underuse and low prevalence of LDL-C control among U.S. adults at high risk of coronary heart disease. Am J Med Sci. 2014;348(2):108-114.
28. van 't Hof FN, Ruigrok YM, Baas AF, et al. Impact of inherited genetic variants associated with lipid profile, hypertension, and coronary artery disease on the risk of intracranial and abdominal aortic aneurysms. Circ Cardiovasc Genet. 2013;6(3): 264-270.
29. Hingorani A, Humphries S. Natures randomised trials. Lancet. 2005;366(9501): 1906-1908.
30. Swerdlow DI, Preiss D, Kuchenbaecker KB, et al; DIAGRAM Consortium; MAGIC Consortium; InterAct Consortium. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2015;385(9965):351-361.
31. Sofat R, Hingorani AD, Smeeth L, et al. Separating the mechanism-based and off-Target actions of CETP-inhibitors with CETP gene polymorphisms. Circulation. 2010;121(1):52-62.
32. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40(4):304-314.
33. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512-525.
34. Willer CJ, Schmidt EM, Sengupta S, et al; Global Lipids Genetics Consortium. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45(11):1274-1283.
35. Burgess S, Thompson SG. Multivariable Mendelian randomization: The use of pleiotropic genetic variants to estimate causal effects. Am J Epidemiol. 2015;181(4):251-260.
36. Yavorska OO, Burgess S. Mendelian Randomization: An R package for performing Mendelian randomization analyses using summarized data. Int J Epidemiol. 2017.
37. HolmesMV, Asselbergs FW, Palmer TM, et al; UCLEB consortium. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J. 2015;36(9):539-550.
38. HolmesMV, Ala-Korpela M, Smith GD. Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. Nat Rev Cardiol. 2017;14(10):577-590.
39. Sabatine MS, Giugliano RP, Keech AC, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18): 1713-1722.
40. Schmidt AF, Swerdlow DI, HolmesMV, et al; LifeLines Cohort Study Group; UCLEB consortium. PCSK9 genetic variants and risk of type 2 diabetes: A mendelian randomisation study. Lancet Diabetes Endocrinol. 2017;5(2):97-105.
41. Smith JG, Luk K, Schulz CA, et al; Cohorts for Heart and Aging Research in Genetic Epidemiology (CHARGE) Extracoronary CalciumWorking Group. Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. JAMA. 2014;312(17):1764-1771.
42. Plenge RM. Disciplined approach to drug discovery and early development. Sci Transl Med. 2016;8(349):349ps15.
43. Cao C, Moult J. GWAS and drug targets. BMC Genomics. 2014;15(suppl 4):S5.
44. Golledge J, van Bockxmeer F, Jamrozik K, McCann M, Norman PE. Association between serum lipoproteins and abdominal aortic aneurysm. Am J Cardiol. 2010;105(10):1480-1484.
45. Forsdahl SH, Singh K, Solberg S, Jacobsen BK. Risk factors for abdominal aortic aneurysms: A 7-year prospective study: The Tromsø Study, 1994-2001. Circulation. 2009;119(16):2202-2208.
46. HPS THRIVE Collaborative Group; Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3): 203-212.
47. Fayad ZA, Mani V, Woodward M, et al; dal-PLAQUE Investigators. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): A randomised clinical trial. Lancet. 2011;378 (9802):1547-1559.
48. Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample Mendelian randomization. Genet Epidemiol. 2016;40(7): 597-608.
49. Dastani Z, HivertMF, Timpson N, et al; DIAGRAM+ Consortium; MAGIC Consortium; GLGC Investigators; MuTHER Consortium; DIAGRAM Consortium; GIANT Consortium; Global B Pgen Consortium; Procardis Consortium; MAGIC investigators; GLGC Consortium. Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: A multi-ethnic meta-Analysis of 45, 891 individuals. PLoS Genet. 2012;8(3):e1002607.